The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | PNK-007: allogeneic NK-cell product post-ASCT in MM
Ravi Vij, MD, MBA, Washington University School of Medicine, Saint Louis, MO, discusses the phase I study (NCT02955550) of single infusion PNK-007, an allogeneic cell therapy product enriched for CD56+/CD3- NK-cells expanded from placental CD34+ cells, after autologous stem cell transplant (ASCT) in multiple myeloma (MM). Prof. Vij reveals PNK-007 with and without recombinant human IL-2 was well tolerated in the post-ASCT setting. Data from this phase I study are encouraging and warrant further evaluation. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
